Effects of CDX2 on prognosis and chemotherapy responsiveness in mismatch repair-deficient colorectal cancer.
Éanna J RyanBen CreavinY L KhawM E KellyH M MohanR GeraghtyE J RyanR KennellyA HanlyS T MartinD FennellyR McDermottD GibbonsP R O'ConnellK SheahanD C WinterPublished in: BJS open (2018)
CDX2- does not confer a worse prognosis in the dMMR phenotype of colorectal cancer. The MMR status of patients with colorectal cancer should be determined before assessing CDX2 status.